{"publication_id":"f585d82f-ef44-4c56-be90-980cfd58978a","content_hash":"sha256:89f50c13c67aaa4ef9db7b3916d9614fe5dc0c343f86cd64e389efd16228ed44","nodes":[{"id":"f585d82f-ef44-4c56-be90-980cfd58978a","type":"publication","title":"metformin: one bounded, context-dependent signal across receipts"},{"id":"claim_1","type":"claim","text":"Across retrieved source-level receipts for metformin, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?"},{"id":"claim_2","type":"claim","text":"Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis [review; 2010] doi:10.1158/1940-6207.capr-10-0157"},{"id":"claim_3","type":"claim","text":"Finding: A 31% reduction in overall summary relative risk (0.69; 95% confidence interval, 0.61-0.79) was found in subjects taking metformin compared with other antidiabetic drugs."},{"id":"claim_4","type":"claim","text":"Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. [review; 2013] doi:10.1038/ajg.2013.5"},{"id":"claim_5","type":"claim","text":"| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |"},{"id":"claim_6","type":"claim","text":"| outcome-specific | Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and... | directionally favorable | diabetic patients | - | A 31% reduction in overall summary relative risk (0.69; 95% confidence interval, 0.61-0.79) was found in... |"},{"id":"claim_7","type":"claim","text":"| outcome-specific | Anti-diabetic medications and the risk of hepatocellular cancer: a... | directionally favorable | patients with type 2 diabetes mellitus | - | a 50% reduction in HCC incidence with metformin use |"},{"id":"claim_8","type":"claim","text":"| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |"},{"id":"claim_9","type":"claim","text":"This receipt-backed scoping note has one bounded signal: metformin shows endpoint-specific favorable signals with context limits across this 5-source primary/review bundle (2010-2022). Evidence role grouping: direction-bearing receipts: 4; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 1 excluded from effect support. The source facts cover 5 population/setting context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim. Concrete contrast: other/mixed: Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients: Mitochondria from the type 2 diabetic patients not treated with metformin displayed more reactive oxygen...; directionally favorable: Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus: Chronic treatment with metformin for 24 weeks improved cognitive performance, as assessed by the Wechsler...."},{"id":"claim_10","type":"claim","text":"null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable."},{"id":"claim_11","type":"claim","text":"directionally favorable: Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis — A 31% reduction in overall summary relative risk (0.69; 95% confidence interval, 0.61-0.79) was found in subjects taking metformin compared with other antidiabetic drugs."},{"id":"claim_12","type":"claim","text":"directionally favorable: Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. — a 50% reduction in HCC incidence with metformin use"},{"id":"claim_13","type":"claim","text":"Evidence role summary: direction-bearing receipts: 4; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 1 excluded from effect support."},{"id":"claim_14","type":"claim","text":"Specific moderators in this bundle are outcome type (Wechsler Memory Scale-Revised cognitive performance; overall survival (OS)), population/indication (Depressed patients with type 2 diabetes mellitus; diabetic lung cancer patients; diabetic patients; patients with type 2 diabetes mellitus; type 2 diabetic patients), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable."},{"id":"claim_15","type":"claim","text":"Population/settings are separated as receipt context: Depressed patients with type 2 diabetes mellitus, diabetic lung cancer patients, diabetic patients, patients with type 2 diabetes mellitus, and type 2 diabetic patients. The selected receipts group because each carries a fact-level extraction for metformin; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim."},{"id":"claim_16","type":"claim","text":"The signal is purely descriptive of source-level direction and scope; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate."},{"id":"source_1","type":"source","study":"Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus","year":2014,"doi":"10.1111/1440-1681.12265","url":"https://doi.org/10.1111/1440-1681.12265","population":"Depressed patients with type 2 diabetes mellitus","intervention_or_exposure":"Metformin 24-week chronic treatment","comparator":"not extracted","endpoint":"Wechsler Memory Scale-Revised cognitive performance","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies","year":2017,"doi":"10.7150/jca.19750","url":"https://doi.org/10.7150/jca.19750","population":"diabetic lung cancer patients","intervention_or_exposure":"metformin treatment","comparator":"not extracted","endpoint":"overall survival (OS)","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_3","type":"source","study":"Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients","year":2022,"doi":"10.1016/j.redox.2022.102342","url":"https://doi.org/10.1016/j.redox.2022.102342","population":"type 2 diabetic patients","intervention_or_exposure":"metformin treatment","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis","year":2010,"doi":"10.1158/1940-6207.capr-10-0157","url":"https://doi.org/10.1158/1940-6207.capr-10-0157","population":"diabetic patients","intervention_or_exposure":"metformin","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_5","type":"source","study":"Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.","year":2013,"doi":"10.1038/ajg.2013.5","url":"https://doi.org/10.1038/ajg.2013.5","population":"patients with type 2 diabetes mellitus","intervention_or_exposure":"metformin","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}],"edges":[{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_1","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_2","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_3","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_4","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_5","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_6","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_7","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_8","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_9","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_10","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_11","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_12","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_13","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_14","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_15","type":"contains_claim"},{"from":"f585d82f-ef44-4c56-be90-980cfd58978a","to":"claim_16","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}